Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$693K Buy
7,000
+800
+13% +$96.4K ﹤0.01% 3273
2026
Q2
$826K Buy
+6,200
New +$702K ﹤0.01% 2907
2026
Q1
– Sell
-500,000
Closed -$67.4M – 5003
2025
Q4
$67.4M Buy
+500,000
New +$54.6M 0.02% 639

Other funds holding ABVX

Barclays's ABVX Position: Q3 2026 in Review

Barclays increased its Abivax (ABVX) stake by 1,539% in Q3 2026, buying an estimated $9.09M and bringing the position to 80,292 shares worth $7.95M. The position accounts for ﹤0.01% of the portfolio, ranked #1778.

Barclays first reported a position in ABVX in Q4 2024 and has held it in 8 quarters since. The position peaked at $41.6M in Q4 2025. 319 funds tracked by Wall St. Rank hold ABVX as of Q3 2026.

  • Barclays held 80,292 shares of Abivax worth $7.95M as of Q3 2026.
  • Barclays bought 75,393 Abivax shares in Q3 2026, an estimated $9.09M.
  • Abivax made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #1778 holding.
  • Barclays first reported a position in Abivax in Q4 2024 and has held it in 8 quarters since.
  • Barclays's Abivax position peaked at $41.6M in Q4 2025.
  • 319 funds tracked by Wall St. Rank held Abivax as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.